A2 Biotherapeutics, Inc.

Our paper on a clinical diagnostic to detect human leukocyte antigen (HLA) loss of heterozygosity (LOH) was just published in Nature Precision Oncology! Rapid and routine HLA assessment is critical for current and emerging immunotherapies, and loss of specific HLA alleles in tumor tissue provides a novel therapeutic opportunity that is key to the investigational products at A2 Bio. Our diagnostic partner, Tempus AI, developed an investigational assay for detection of the loss of HLA alleles that is seamlessly integrated into their standard xT CDx. This enables efficient HLA assessment, and identification of patients potentially eligible for our pre-screening study, BASECAMP-1 (NCT04981119) and subsequent therapeutic studies EVEREST-1 (NCT05736731) and EVEREST-2 (NCT06051695). This paper describes the technical details of the clinical diagnostic and demonstrates the biological relevance of HLA-LOH for patients with lung cancer. #precisionmedicine #HLA #BiologyNews #Oncology #A2Bio Below is a link to the article: https://lnkd.in/gZjttYXp

Last week, we hosted our first "Bring Your Kids to Work Day" at our A2 Bio campus in Agoura Hills, CA. It was heartwarming to see 32 kids having so much fun learning about our science and exploring our facilities. Special thanks to our A2 Bio volunteers for making a great work experience for kids, inspiring them to be curious about their future careers and have fun. The kids participated in hands-on science experiments, had the opportunity to tour our labs, and hear from A2 leaders on what inspired them to pursue a career in biotechnology. #A2 Bio #Biotech #CellTherapy #TakeYourKidsToWork

A2 Biotherapeutics is pleased to announce the appointment of Ryan Card as general counsel. Ryan will be responsible for leading the legal function for A2 Bio, a clinical-stage biotechnology company developing first-in-class logic-gated cell therapies for solid tumors, based in Agoura Hills, California. Before joining A2 Bio, Ryan served as executive vice president, general counsel and chief compliance officer of Urovant Sciences until the company’s merger into Sumitomo Pharma America in 2023. In this role, he led Urovant's legal and compliance functions through the successful launch of the company's first commercial product in the United States, GEMTESA® (vibegron). Prior to joining Urovant, Ryan was executive director, senior counsel with Allergan plc, where he worked as chief counsel for the company’s neurology, eye care, and urology business units, which included the company's BOTOX therapeutic franchise. Previously, Ryan was a senior litigation associate with Gibson, Dunn & Crutcher, LLP. He earned a bachelor of science degree from the University of Utah and his law degree from Brigham Young University Law School. #Biotech #OncologyNews #CellTherapy #A2 Bio

A2 Bio celebrated our annual summer picnic last week in beautiful Agoura Hills, CA. It was a wonderful turnout that brought our staff, friends, and family together to share food, ice cream, and games. Special thanks to all who attended for making this such a memorable event. #A2Bio #CellTherapy #Tmod #Biotech #Oncology #Agoura Hills

At A2 Bio, we are working together for a better tomorrow for patients with cancer. To tackle such an ambitious goal, we need the help of a dedicated team of scientists, manufacturers, and industry professionals from diverse backgrounds. Together we can work effectively and efficiently to support patients. A2 Bio is proud to support Pride month and the LGBTQ+ community.  

A2 Bio is proud to announce the launch of its new A2bioclinicaltrials.com website. We've designed the website to provide Patients & Caregivers information on our clinical studies, including infographics to help explain the patient journey. The site also includes a section to support healthcare providers with information on our pre-screening, observational study, BASECAMP-1, to identify participants who might benefit from future Tmod CAR T-cell therapy in our investigational studies. A2 Bio would like to thank the clinical sites, teams, and patients for providing the inspiration and encouragement to launch this new website. Visit our new site: https://lnkd.in/g2JF-ANQ #A2Bio #Tmod #Biotech #CellTherapy #clinicaltrials #innovation #biotechnews #TCells #CarT

A2 Bio is proud to present updates on three ongoing clinical trials in poster presentation at ASCO 2024. The poster presentations are scheduled on Saturday, June 1st from 9:00 - 12:00 pm CT. For more information on our clinical trials, please go to https://lnkd.in/ge7KqZ8T To view the press release: https://lnkd.in/g6RRrgig #BiologyNews #Oncology #A2Bio #Tmod #ASCO24

A2 Bio was proud to be a sponsor of the Los Angeles Bioscience Ecosystem Summit Twenty24 (LABEST). Los Angeles is at the forefront of biotech innovation, and we are grateful to the UCLA Technology Development Group (UCLA TDG) for hosting a wonderful event. Our new CEO, Jim Robinson, served as a panelist on the "Made in LA: Case Studies in Bio Success" session and highlighted the exciting progress being made at A2 Bio. We had a great showing from the A2 Bio team and look forward to next year! #A2Bio #CellTherapy #Tmod #Biotech #Oncology #LABEST

A2 is proud to announce the presentation of the recent journal article 'Geometric parameters that affect the behavior of logic-gated CAR T cells' at the international PEGS protein and cell engineering summit in Boston. The findings demonstrate the utility of A2 Bio's platform beyond HLA proteins, greatly expanding the applicability of Tmod into other indications. The paper was presented by the lead author, Alex Partin and was awarded best poster based on the clarity and novelty of the data, technology advances and implications of the work presented, and a clear and engaging oral explanation. Congratulations to Alex and the team for this excellent achievement! Link to Poster: https://lnkd.in/g-q2viTs #BiologyNews #Oncology #A2Bio #Tmod

A2 Bio is proud to announce a new journal article published in iScience entitled, "NOT gated T cells that selectively target EGFR and other widely expressed tumor antigens." Discrimination between tumor and normal tissue is the fundamental challenge in cancer drug discovery. A2 Bio's Tmod system utilizes an inhibitory receptor gated by specific HLA alleles to control a CAR or TCR activator. This paper demonstrates that EGFR can be used as the target for a potent Tmod cell therapy that spares normal tissues across a broad range of antigen expression. Furthermore, it shows that the Tmod system works in the complex milieu of a mouse body, targeting mouse homologs of EGFR and HLA. Congratulations to Julie Oh, Charlie Kirsch, and the A2 Bio discovery research team for this important publication. For the full article, please access via the link below: https://lnkd.in/gQvQ-qbw Here are the highlights of the paper: 1. The Tmod NOT gate can target widely expressed antigens such as EGFR and HLA-E 2. Tmod works in mice, targeting mouse homologs of EGFR and HLA to kill tumors 3. Ligand-dependent CAR removal may facilitate Tmod localization to the tumor site 4. Tmod inherently resists GvHD without gene edits, a benefit for allogeneic products #BiologyNews #Oncology #A2Bio #Tmod